Drugs for Recurrent Respiratory Papillomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 36)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cidofovir |
Approved |
Phase 4,Phase 2 |
|
113852-37-2 |
60613
|
Synonyms:
({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
(2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine
(S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid
(s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
(S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
(S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
(S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine
(S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine
(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid
(S)-HPMPC
[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
[(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid
[[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid
1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine
1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine
1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate
113852-37-2
120362-37-0 (hydrochloride salt)
149394-66-1
AC-1666
AC1L1TLB
AC1Q6C68
AKOS005145721
C8H14N3O6P
|
CDV
CHEBI:3696
CHEMBL152
CID60613
Cidofovir
Cidofovir (anhydrous)
Cidofovir (Vistide)
Cidofovir anhydrous
Cidofovir Anhydrous
Cidofovirum
DB00369
Forvade
GS 0504
GS 504
GS-0504
GS504
GS-504
HPMPC
HSDB 7115
LS-106432
MolPort-005-935-597
NSC742135
S1516_Selleck
UNII-768M1V522C
Vistide
Vistide, Cidofovir
|
|
2 |
|
Anti-Infective Agents |
|
Phase 4,Phase 2 |
|
|
|
3 |
|
Antiviral Agents |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
4 |
|
Vaccines |
|
Phase 3,Early Phase 1 |
|
|
|
5 |
|
Immunoglobulins |
|
Phase 3,Phase 2 |
|
|
|
6 |
|
Antibodies |
|
Phase 3,Phase 2 |
|
|
|
7 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662
|
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
8 |
|
Bevacizumab |
Approved, Investigational |
Phase 2,Phase 1 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
|
|
9 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
|
Synonyms:
|
10 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
68-26-8, 11103-57-4 |
445354
|
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
[11,12-3H]-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
alin
All Trans Retinol
All-trans retinol
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-retinol
all-trans-Retinol
All-trans-Retinol
all-trans-retinyl alcohol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-vitamin A alcohol
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
Alphalin
Alphasterol
A-Mulsal
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A Parenteral
Aquasynth
AR-1L3057
A-Sol
Atars
ATAV
Avibon
A-Vi-Pel
Avita
A-Vitan
Avitol
Axerol
Axerophthol
Axerophtholum
Bentavit A
beta-Retinol
BIDD:PXR0102
Biosterol
b-Retinol
BRN 0403040
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
Chocola A
CID445354
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
Hi-A-Vita
HMS1921B04
HMS2092L13
|
HMS501I08
Homagenets Aoral
Homagenets aorl
HSDB 815
Hydrovit A
IDI1_000486
Lard Factor
LMPR01090001
LPK
LS-1578
M.V.C. 9+3
M.V.I.-12
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
Nio-A-Let
NSC 122759
NSC122759
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
retinol
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol-(cellular-retinol-binding-protein)
Retinol, all-trans- (8CI)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
Sehkraft A
SMP2_000102
SMR000112036
Solu-A
SPECTRUM1501203
Spectrum5_000993
Spectrum5_001997
ST057232
Super A
Testavol
Testavol S
Thalasphere
trans-retinol
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
tROL
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-a
Vi-Alpha
Vi-Dom-A
Vio-A
Vitamin A
Vitamin- A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin- A alcohol
Vitamin A alcohol (VAN)
Vitamin- A alcohol solution
Vitamin A cryst
Vitamin A1
Vitamin- A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
Wachstumsvitamin
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
ZINC03831417
Zinosan N
|
|
11 |
|
Analgesics |
|
Phase 2 |
|
|
|
12 |
|
Cyclooxygenase 2 Inhibitors |
|
Phase 2 |
|
|
|
13 |
|
Cyclooxygenase Inhibitors |
|
Phase 2 |
|
|
|
14 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
15 |
|
Angiogenesis Inhibitors |
|
Phase 2,Phase 1 |
|
|
|
16 |
|
Angiogenesis Modulating Agents |
|
Phase 2,Phase 1 |
|
|
|
17 |
|
Peripheral Nervous System Agents |
|
Phase 2 |
|
|
|
18 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
19 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
20 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
21 |
|
Retinol palmitate |
|
Phase 2 |
|
|
|
22 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
23 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
24 |
|
retinol |
Nutraceutical |
Phase 2 |
|
|
|
25 |
|
Vitamin D |
Approved, Nutraceutical, Vet_approved |
Phase 1 |
|
1406-16-2 |
|
Synonyms:
|
Vitamin D, unspecified form
|
|
26 |
|
Ergocalciferol |
Approved, Nutraceutical |
Phase 1 |
|
50-14-6 |
5280793
|
Synonyms:
(+)-Vitamin D2
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
47768_SUPELCO
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
beta-Ol
bmse000510
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
Calciferolum
Calciferon 2
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
component of Geltabs Vitamin D
Condacaps
Condocaps
Condol
Crtron
Crystallina
D00187
Daral
D-Arthin
Davitamon D
Davitin
DB00153
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
delta-Arthin
Deltalin
delta-Tracetten
De-rat concentrate
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
D-Tracetten
E5750_SIGMA
EINECS 200-014-9
Ercalciol
ergocalciferol
Ergocalciferol
Ergocalciférol
Ergocalciferol (D2)
|
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
'Ergosterol irradiated'
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
Haliver
Hi-Deratol
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
Metadee
Mina D2
MLS001332467
MLS001332468
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
Novovitamin-D
NSC 62792
NSC62792
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick_554
Prestwick3_000420
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
Shock-ferol
Shock-ferol sterogyl
SMR000857106
Sorex C.R
Sorex C.R.
SPECTRUM1500276
Spectrum5_000666
ST057150
Sterogyl
STOCK1N-53397
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
vitamin d-2
Vitamin D2
Vitamin- D2
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
Vitamin-?D2
VITAMIN_D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
|
|
27 |
|
Micronutrients |
|
Phase 1 |
|
|
|
28 |
|
Trace Elements |
|
Phase 1 |
|
|
|
29 |
|
Vitamins |
|
Phase 1 |
|
|
|
30 |
|
Ergocalciferols |
|
Phase 1 |
|
|
|
31 |
|
Bone Density Conservation Agents |
|
Phase 1 |
|
|
|
32 |
|
Vitamin D2 |
Nutraceutical |
Phase 1 |
|
|
|
33 |
|
Calciferol |
Nutraceutical |
Phase 1 |
|
|
|
34 |
|
3,3'-diindolylmethane |
Investigational |
|
|
1968-05-4 |
|
Synonyms:
|
35 |
|
Pepsin A |
|
|
|
|
|
36 |
|
Protective Agents |
|
|
|
|
|
Interventional clinical trials:
(show all 20)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Use of Cidofovir for Recurrent Respiratory Papillomatosis |
Completed |
NCT00205374
|
Phase 4 |
Cidofovir;Placebo |
2 |
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") |
Terminated |
NCT00747461
|
Phase 4 |
|
3 |
4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children |
Unknown status |
NCT01995721
|
Phase 3 |
|
4 |
Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis |
Active, not recruiting |
NCT01375868
|
Phase 3 |
|
5 |
Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis |
Withdrawn |
NCT01058317
|
Phase 2, Phase 3 |
Propranolol |
6 |
Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis |
Completed |
NCT00571701
|
Phase 2 |
celebrex (celecoxib);placebo |
7 |
A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis |
Completed |
NCT00038714
|
Phase 2 |
SGN-00101 |
8 |
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis |
Recruiting |
NCT02555800
|
Phase 2 |
Bevacizumab;Cidofovir |
9 |
Avelumab for People With Recurrent Respiratory Papillomatosis |
Recruiting |
NCT02859454
|
Phase 2 |
Avelumab |
10 |
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement |
Recruiting |
NCT02632344
|
Phase 2 |
Pembrolizumab |
11 |
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP) |
Completed |
NCT01020747
|
Phase 1 |
Avastin® (bevacizumab);Saline |
12 |
Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP) |
Not yet recruiting |
NCT02854761
|
Phase 1 |
EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) |
13 |
Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease |
Withdrawn |
NCT00733252
|
Phase 1 |
|
14 |
Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP |
Completed |
NCT00550914
|
|
|
15 |
Human Papillomatosis Genotyping of Children in Thailand |
Completed |
NCT01304966
|
|
|
16 |
Human Papillomavirus 6/11 in the Lower Airway of Neonates |
Completed |
NCT00549250
|
|
|
17 |
Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions |
Completed |
NCT02217358
|
|
|
18 |
Recurrent Respiratory Papillomatosis and Extraesophageal Reflux |
Recruiting |
NCT02592902
|
|
|
19 |
New Therapy of Laryngeal Papilloma In Children |
Terminated |
NCT00591305
|
|
|
20 |
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis |
Withdrawn |
NCT00829608
|
Early Phase 1 |
|
|